HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH)

References

• Le GM, Gomez SL, Clarke CA, Glaser SL, West DW. Cancer incidence patterns among Vietnamese in the United States and Ha Noi, Vietnam. Int J Cancer 2002;102:412–7.
   PubMed Web of Science ®Google Scholar
• Lin SS, Phan JC, Lin AY. Breast cancer characteristics of Vietnamese women in the Greater San Francisco Bay Area. West J Med 2002;176:87–91.
   PubMedGoogle Scholar
• Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287–312.
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Andersson M, Christensen IJ, Moller S. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002–2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol 2008;47: 784–8.
   PubMedGoogle Scholar
• Cuadros M, Villegas R. Systematic review of HER2 breast cancer testing. Appl Immunohistochem Mol Morphol 2009;17:1–7.
   PubMedGoogle Scholar
• Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect 2009;22: 93–106.
   PubMed Web of Science ®Google Scholar
• Capizzi E, Gruppioni E, Grigioni AD, Gabusi E, Grassigli A, Grigioni WF, . Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: A comparative study with FISH, SISH, and immunohistochemistry. Diagn Mol Pathol 2008;17:220–6.
   PubMedGoogle Scholar
• Francis GD, Jones MA, Beadle GF, Stein SR. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: Correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 2009;18:88–95.
   PubMed Web of Science ®Google Scholar
• Dietel M, Ellis IO, Hofler H, Kreipe H, Moch H, Dankof A, . Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch 2007;451:19–25.
   PubMed Web of Science ®Google Scholar
• Carbone A, Botti G, Gloghini A, Simone G, Truini M, Curcio MP, . Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn 2008;10: 527–36.
   PubMed Web of Science ®Google Scholar
• Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, . Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003;21:453–7.
   PubMedGoogle Scholar
• Zeng X, Liang ZY, Wu SF, Gao J, Zhou WX, Liu TH. [HER2 status in breast cancer of Chinese women: A study of 1170 cases using fluorescence in-situ hybridization]. Zhonghua Bing Li Xue Za Zhi 2008;37:594–8. Chinese.
   PubMedGoogle Scholar
• Beeghly-Fadiel A, Kataoka N, Shu XO, Cai Q, Deming SL, Gao YT, . Her-2/neu amplification and breast cancer survival: Results from the Shanghai breast cancer study. Oncol Rep 2008;19:1347–54.
   PubMed Web of Science ®Google Scholar
• Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, . HER2 status in a population-derived breast cancer cohort: Discordances during tumor progression. Breast Cancer Res Treat Epub 2010 Jul 14.
   Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320–68.
   PubMed Web of Science ®Google Scholar
• Bartlett JM, Campbell FM, Ibrahim M, Wencyk P, Ellis I, Kay E, . Chromogenic in situ hybridization: A multicenter study comparing silver in situ hybridization with FISH. Am J Clin Pathol 2009;132:514–20.
   PubMedGoogle Scholar
• Papouchado BG, Myles J, Lloyd RV, Stoler M, Oliveira AM, Downs-Kelly E, . Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: Comparison with FISH and assessment of interobserver reproducibility. Am J Surg Pathol 2010;34:767–76.
   PubMedGoogle Scholar
• Kurosumi M. Recent trends of HER-2 testing and trastuzumab therapy for breast cancer. Breast Cancer 2009;16: 284–7.
   PubMedGoogle Scholar
• Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, . A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 2003;98:1587–95.
   PubMedGoogle Scholar
• Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J 2005;11:278–80.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang X, Nie X, Ma L. Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients. J Huazhong Univ Sci Technolog Med Sci 2009;29:354–8.
   PubMedGoogle Scholar
• Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, . Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer. Oncol Rep 2008;19:651–6.
   PubMedGoogle Scholar
• Ratnatunga N, Liyanapathirana LV. Hormone receptor expression and Her/2neu amplification in breast carcinoma in a cohort of Sri Lankans. Ceylon Med J 2007;52:133–6.
   PubMedGoogle Scholar
• Borresen AL, Ottestad L, Gaustad A, Andersen TI, Heikkila R, Jahnsen T, . Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: Relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 1990;62:585–90.
   PubMed Web of Science ®Google Scholar
• Yau TK, Sze H, Soong IS, Hioe F, Khoo US, Lee AW. HER2 overexpression of breast cancers in Hong Kong: Prevalence and concordance between immunohistochemistry and in-situ hybridisation assays. Hong Kong Med J 2008; 14:130–5.
   PubMedGoogle Scholar